Advanced Analytics

Download our latest eBook to learn how TriNetX is combining the world’s largest RWD network with advanced AI to accelerate protocol design, site selection, and patient recruitment.

We are honored to share that TriNetX has won the “Clinical Trial Innovation Award” in the 10th annual MedTech Breakthrough Awards.

Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Technology Solutions Worldwide. [External]

By partnering with TriNetX, one global pharma organization embedded real‑world data and transparent AI‑enabled query translation directly into existing design workflows.

Clinical development costs now average roughly $708 million per approved therapy. The industry’s need for accessible and trustworthy insight from real‑world data has never been greater.

We spotlight Tasfia’s work at Penn State and distilling practical lessons for other researchers navigating the complexities of cohort-based RWE studies.

TriNetX, the world’s leading federated health data network, today announced that it has acquired the key assets of Zetta Genomics, a Cambridge, UK-based healthcare technology company and current TriNetX partner.

Regeneron Pharmaceuticals, Inc. and TriNetX® today announced a strategic collaboration to support Regeneron’s capabilities in drug discovery and development, as well as new initiatives to deliver digital health solutions of the future for consumers, patients and providers.

We explore how clinical data integration unifies disparate systems to deliver actionable insights.

In our latest Inside the Trends vodcast episode, COO Steve Kundrot spoke with Dr. Sarju Ganatra , a cardiologist and Co-Director of the Lahey Innovation Hub. They stripped patient-centricity back to its core.

TriNetX is proud to announce that we were named a Best of Show Finalist at SCOPE, the summit for clinical ops executives, one of the industry’s premier events focused on advancing clinical operations and innovation.

Patient-centricity is everywhere in clinical research. But what does it actually look like inside real healthcare systems?

Success achieved in reducing trial costs and timelines drives 2026 platform enhancements designed to democratize clinical research analytics.

As we step into 2026, explore the resources that captivated our community in 2025, and more importantly, why they mattered.

In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, all participants agreed that real-world evidence has the potential to improve regulatory submissions, underscoring the urgency for sponsors to integrate RWE more strategically into their regulatory playbooks.

As 2025 wraps up, the TriNetX team is reflecting on a year of milestones, among them, being named to The Healthcare Technology Report’s Top 50 Healthcare Technology Companies list this November.

To succeed, biotechs are rethinking how clinical research gets done. RWD, AI, and patient-centric strategies are no longer experimental; they’re emerging as the core toolkit for companies determined to accelerate progress while controlling risk.

Real-world data (RWD) plays a crucial role in clinical research and decision-making, yet navigating its complexity remains a significant challenge. RWD typically comes from claims—open or closed—or from electronic health records (EHRs).

Discover why TriNetX is the most-cited EHR dataset in peer-reviewed publications. Explore how our high-quality real-world data (RWD) powers high-impact research in top-tier medical journals and drives global breakthroughs in real-world evidence.

Clinical trials are the cornerstone of medical advancements, playing a pivotal role in the development of new treatments, interventions and understanding of diseases.

In my role at TriNetX, I have the privilege of engaging with leaders across the clinical research landscape who are challenging the status quo and pushing us toward a more inclusive, tech-enabled, and patient-first future.

The clinical research landscape is evolving, and the demand for faster, more efficient trials has never been greater. From restrictive protocols, fragmented processes, and a never-ending amendment cycles.

What happens when clinical research is redesigned around the needs, preferences, and lives of real people? In this episode of The Future Prescription: Inside the Trends, discover how sponsors and CROs are aligning clinical and commercial priorities to create smarter, more inclusive, and scalable studies.

As clinical trials evolve, one thing is certain: representativeness is no longer a nice-to-have; it’s a non-negotiable. The data are clear. In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, 84% reported ramping up efforts to improve representativeness and accessibility in clinical research over the past few years.

Sanofi UK, a leading pharmaceutical company, sought an innovative solution to address challenges in clinical trial recruitment and feasibility.

In just a few years, real-world data (RWD) has evolved from an industry buzzword to a core driver of progress in drug development. What used to be experimental is now operational and increasingly essential. In the 2025 TriNetX and studioID survey of 150 senior biopharma executives, more than three-quarters said their organizations are already applying RWD across some part of the drug development lifecycle. We’re clearly well beyond the pilot phase.

Analysis reveals strategic opportunities for pharmaceutical leaders to close treatment gaps and accelerate breakthroughs in underserved rare disease communities.

Real-world data (RWD), artificial intelligence (AI), and patient-centric trial design lead pharma priorities in 2025, but data compatibility, regulatory hurdles, and security concerns threaten to stall momentum.

Clinical trials often falter at the final stretch—when it’s time to execute. It’s here that well-intentioned protocols meet real-world complexity, where timelines can slip, costs may surge, and outcomes could fall short of expectations.

In the high-stakes world of clinical research, innovation doesn’t just happen in the lab; it must cross the clinical trial finish line of regulatory submission. Yet for many sponsors, sites, and researchers, patient recruitment—or the “last mile”—remains a costly bottleneck where recruitment can lag, site enrollment can underperform, and promising treatments never receive approval.

The “last mile” of clinical research represents the crucial phase where protocols are put into action, and patient engagement becomes a reality. It’s about transforming well-laid plans into meaningful outcomes by efficiently connecting researchers, sites, and participants.

Clinical trials are being reinvented by real-world data (RWD). In 2025, data-driven strategies won’t just complement trial design—they’ll define it. From protocol optimization to accelerated site identification, data is the new compass guiding clinical innovation

The result? Higher costs, longer timelines, and compromised outcomes. The need to solve these critical challenges has never been more urgent.

Combining disparate data sources to inform clinical trial site selection has long been a complex challenge. Inconsistent site naming, differences in the definition of a site, and a lack of potential patient counts, among other obstacles, have made it difficult for sponsors to pinpoint optimal sites.  

Real-world data (RWD) and the real-world evidence (RWE) derived from analysis of the data are a cornerstone of clinical advancements in today’s fast-paced research environment

The healthcare and clinical research industries are undergoing a seismic shift. Rapid advancements in real-world data (RWD), artificial intelligence (AI), and patient-centric approaches are rewriting the playbook for clinical trials and treatment development. The future of healthcare is here, and organizations that embrace these changes will be at the forefront of innovation. 

Clinical trial site identification (ID) and outreach are often inefficient due to manual, paper-based processes, placing a heavy burden on both contract research organizations (CROs) and the clinical study sites with which they work.

Clinical trials are vital to drug development but often face challenges such as slow patient recruitment, high costs, and suboptimal trial designs. Today, artificial intelligence (AI) and real-world data (RWD) are transforming this process by optimizing trial protocols, enhancing recruitment, and accelerating timelines.  

Clinical trials are the backbone of medical advancements, yet they often face significant hurdles in their final stages.

In the evolving landscape of clinical research, the era of one-size-fits-all clinical trials is firmly behind us. Regulatory bodies and industry leaders alike recognize the necessity of diverse representation in trials to ensure that medical treatments are effective for all populations.

The integration of digital technology is transforming clinical research, improving the efficiency of trial design and execution. A key innovation in this space is the digital waiting room, which leverages real-world data (RWD) and artificial intelligence (AI) to enhance the critical “last mile” of a trial—when sites are activated, and patient recruitment begins. 

SCOPE 2025, held from February 3-6 in Orlando, Florida, brought together over 4,500 leaders in clinical operations and research to discuss the latest advancements in clinical trial innovation, planning, management, and operations

Partnership taps real-world data to accelerate clinical trials, research, and drug development in Japan.   

In a rapidly evolving healthcare landscape, artificial intelligence (AI) is emerging as a transformative force in drug development and clinical research. With the average cost of bringing a new drug to market soaring to $1.3 billion and a low probability of success, the stakes for innovation have never been higher.

Clinical trials are the bedrock of medical advancement, but they often grapple with a persistent challenge: ensuring diverse and representative participation. This issue isn’t just a matter of ethics—it’s crucial for delivering effective, equitable healthcare solutions.   

After 11 Years, Gadi Lachman to Conclude Operating Role, Remain on TriNetX’s Board

In an era defined by rapid advancements in technology and science, healthcare research and clinical trials are undergoing a transformative shift. At the heart of this revolution is data—vast, diverse, and ever-growing—and the collaborative efforts of stakeholders across the healthcare ecosystem.

In June 2024, the U.S. Food and Drug Administration (FDA) issued draft guidance outlining the need for “Diversity Action Plans” as a way for clinical trial sponsors to demonstrate their consideration toward trial representation

Cancer clinical trials have long been the cornerstone of advancements in oncology, guiding the development of new therapies and improving patient outcomes.

Artificial intelligence (AI) has the potential to revolutionize drug development by leveraging real-world data (RWD) from electronic health records, claims data, patient registries, and wearable devices.

Discover an insightful webinar that focuses on the transformative potential of real-world data (RWD) in clinical research and healthcare strategy.

The landscape of clinical trials is evolving, and with it, the approach to site selection. A more patient-centric model is emerging, which flips the traditional process on its head.  

Company recognized with high-level certification for abiding by Spain’s strongest data security measures, sets a new standard for healthcare data protection within its TriNetX LIVE™ platform.

Gadi Lachman, President and CEO of TriNetX, discussed the profound impact RWD is having on the healthcare industry in a Crossroads by Alantra podcast episode — Unlocking the Power of Real-World Data — released earlier this month.

“Diversity in clinical trials” is undoubtedly one of the hottest topics in the healthcare industry today and with good reason. Underrepresentation in clinical trials can have significant and wide-ranging consequences

Join us for an insightful webinar that delves into the critical topic of diversity in clinical trials. This event explores using real-world data (RWD) to enhance trial design, promote health equity, and foster robust evidence generation.

Many clinical trials struggle to enroll patients, hindering meaningful results and delaying the delivery of therapies to patients. Real-world data (RWD) addresses this by overcoming barriers such as overly strict enrollment criteria and disconnects between research design and patients’ lived experiences.

Earlier this year, the FDA rejected an application for a new cancer drug because it was based on a trial conducted in China, and the agency ruled it did not represent the U.S. population.

East Lancashire Hospitals NHS Trust (ELHT) is a large, integrated healthcare organization providing high quality acute secondary healthcare for more than 700,000 people of East Lancashire and Blackburn annually.

The MetroHealth System, Cuyahoga County’s public health system, provides care to more than 300,000 patients through nearly 1.5 million visits a year at its four hospitals, and more than 20 health centers throughout the county, which includes Cleveland and surrounding suburbs

The West Virginia Clinical and Translational Science Institute (WVCTSI), a partner of West Virginia University (WVU), is an academic home and a catalyst for clinical and translational research that targets priority health areas including addiction and resulting emerging epidemics such as hepatitis C, cancer, cardiovascular disease, and chronic lung disease.